The United States-based pharmaceutical company Bristol-Myers Squibb has announced it is buying rival US company Celgene in one of the biggest deals in the research-intensive area.
The deal is worth about $74 billion (€65 bn), BMS announced on 3 January. The resulting company will continue to invest in innovation as it seeks to deliver ongoing cost savings of about $2.5bn by 2022, it said.
“The transaction will create a leading focused specialty biopharma company well positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease,” the company said in a press release.
This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com
Pivot-RP users can log in and view the article via this link.